STOCK TITAN

Abeona Therapeutics Inc - ABEO STOCK NEWS

Welcome to our dedicated news page for Abeona Therapeutics (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abeona Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abeona Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
-
Rhea-AI Summary
Abeona Therapeutics changes the date of its First Quarter 2023 Portfolio Update conference call and webcast to May 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
-
Rhea-AI Summary
Abeona Therapeutics announces new data on gene therapy candidates for eye diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.52%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
none
Abeona Therapeutics Inc

Nasdaq:ABEO

ABEO Rankings

ABEO Stock Data

212.27M
19.08M
4.94%
59.94%
7.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ABEO

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t